BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-57. [PMID: 11040201 DOI: 10.1053/gast.2000.18160] [Cited by in Crossref: 254] [Cited by in F6Publishing: 274] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Tao Y, Li C, Gao T, Huo J. Molecular mechanism of Sishen pills in the treatment of diarrheal diabetic enteropathy based on network pharmacology. Medicine (Baltimore) 2022;101:e30096. [PMID: 36107605 DOI: 10.1097/MD.0000000000030096] [Reference Citation Analysis]
2 Xing L, Fu L, Toldrá F, Teng S, Yin Y, Zhang W. The stability of dry‐cured ham‐derived peptides and its anti‐inflammatory effect in RAW264.7 macrophage cells. Int J of Food Sci Tech. [DOI: 10.1111/ijfs.15800] [Reference Citation Analysis]
3 Tang ML, Li H, Ning JF, Shen X, Sun X. Discovery of First-in-Class TAK1-MKK3 Protein-Protein Interaction (PPI) Inhibitor (R)-STU104 for the Treatment of Ulcerative Colitis through Modulating TNF-α Production. J Med Chem 2022. [PMID: 35442672 DOI: 10.1021/acs.jmedchem.1c02198] [Reference Citation Analysis]
4 Ylisaukko-Oja T, Puttonen M, Jokelainen J, Koivusalo M, Tamminen K, Torvinen S, Voutilainen M. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scand J Gastroenterol 2022;57:415-23. [PMID: 34927504 DOI: 10.1080/00365521.2021.2014950] [Reference Citation Analysis]
5 Yu H, Sun H, Wang K, Liang X, Ding Y, Chang X, Guo J, Peng D, Gui SY. Study of the therapeutic effects of Painong powder on ulcerative colitis and the role of Platycodonis Radix in the prescription based on pharmacodynamic, pharmacokinetic, and tissue distribution analyses. J Ethnopharmacol 2022;285:114872. [PMID: 34838618 DOI: 10.1016/j.jep.2021.114872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Skartsis N, Peng Y, Ferreira LMR, Nguyen V, Ronin E, Muller YD, Vincenti F, Tang Q. IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function. Front Immunol 2021;12:783282. [PMID: 35003100 DOI: 10.3389/fimmu.2021.783282] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
7 Hu W, Feng Y, Ye Z, Tang Z, Qian L, Wang Y, Huang Y. The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China. Front Pediatr 2021;9:744599. [PMID: 34966700 DOI: 10.3389/fped.2021.744599] [Reference Citation Analysis]
8 Lauro R, Mannino F, Irrera N, Squadrito F, Altavilla D, Squadrito G, Pallio G, Bitto A. Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review. Biomedicines 2021;9:1748. [PMID: 34944563 DOI: 10.3390/biomedicines9121748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Behl T, Kumar K, Singh S, Sehgal A, Sachdeva M, Bhatia S, Al-harrasi A, Buhas C, Teodora Judea-pusta C, Negrut N, Alexandru Munteanu M, Brisc C, Bungau S. Unveiling the role of polyphenols in diabetic retinopathy. Journal of Functional Foods 2021;85:104608. [DOI: 10.1016/j.jff.2021.104608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Behl T, Kumar K, Singh S, Sehgal A, Sachdeva M, Bhatia S, Al-harrasi A, Buhas C, Teodora Judea-pusta C, Negrut N, Alexandru Munteanu M, Brisc C, Bungau S. Unveiling the role of polyphenols in diabetic retinopathy. Journal of Functional Foods 2021;85:104608. [DOI: 10.1016/j.jff.2021.104608] [Reference Citation Analysis]
11 Pagnini C, Cominelli F. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. Int J Mol Sci 2021;22:10273. [PMID: 34638616 DOI: 10.3390/ijms221910273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Skartsis N, Peng Y, Ferreira LM, Nguyen V, Muller Y, Vincenti F, Tang Q. TNFa and IL-6 promote ex-vivo proliferation of lineage-committed human regulatory T cells.. [DOI: 10.1101/2021.08.09.455690] [Reference Citation Analysis]
13 Reyes‐becerril M, Angulo C, Angulo M, Esteban MÁ. Probiotic properties of Debaryomyces hansenii BCS004 and their immunostimulatory effect in supplemented diets for gilthead seabream ( Sparus aurata ). Aquaculture Research 2021;52:2715-2726. [DOI: 10.1111/are.15123] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Kotze PG, Akiyoshi FK, Luvizotto M, Olandoski M, Kotze LMDS, Coy CSR. Comparative analysis of adverse events between infliximab and adalimumab in Crohn's disease management: a Brazilian single-centre experience. Journal of Coloproctology 2021;33:033-8. [DOI: 10.1016/j.jcol.2013.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sangaran PG, Ibrahim ZA, Chik Z, Mohamed Z, Ahmadiani A. Lipopolysaccharide Pre-conditioning Attenuates Pro-inflammatory Responses and Promotes Cytoprotective Effect in Differentiated PC12 Cell Lines via Pre-activation of Toll-Like Receptor-4 Signaling Pathway Leading to the Inhibition of Caspase-3/Nuclear Factor-κappa B Pathway. Front Cell Neurosci 2020;14:598453. [PMID: 33551748 DOI: 10.3389/fncel.2020.598453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Cockrell C, An G. Multiscale and Tissue Realistic Translational Modeling of Gut Inflammation. Complex Systems and Computational Biology Approaches to Acute Inflammation 2021. [DOI: 10.1007/978-3-030-56510-7_13] [Reference Citation Analysis]
17 Cerboni S, Gehrmann U, Preite S, Mitra S. Cytokine-regulated Th17 plasticity in human health and diseases. Immunology 2021;163:3-18. [PMID: 33064842 DOI: 10.1111/imm.13280] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
18 Matos AL, Bruno DF, Ambrósio AF, Santos PF. The Benefits of Flavonoids in Diabetic Retinopathy. Nutrients 2020;12:E3169. [PMID: 33081260 DOI: 10.3390/nu12103169] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
19 Esterly HJ, Crilly CJ, Piszkiewicz S, Shovlin DJ, Pielak GJ, Christian BE. Toxicity and Immunogenicity of a Tardigrade Cytosolic Abundant Heat Soluble Protein in Mice. Front Pharmacol 2020;11. [DOI: 10.3389/fphar.2020.565969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Salvador-Martín S, Bossacoma F, Pujol-Muncunill G, Navas-López VM, Gallego-Fernández C, Viada J, Muñoz-Codoceo R, Magallares L, Martínez-Ojinaga E, Moreno-Álvarez A, Solar-Boga A, Segarra O, Clemente S, Rodriguez-Martinez A, Alvarez-Vayo C, Loverdos I, Merino-Bohórquez V, Balboa-Vega MJ, Blanca-García JA, Fobelo MJ, Millán-Jiménez A, García-Romero R, Sanchez C, Tolín M, Caldas RG, Eizaguirre FJ, Sánchez-Hernandez JG, Torres-Peral R, Aznal E, García-González X, Sanjurjo-Sáez M, López-Fernández LA. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020;71:508-15. [PMID: 32773718 DOI: 10.1097/MPG.0000000000002840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Gao XZ, Zhang ZX, Han GL. MiR-29a-3p Enhances the Viability of Rat Neuronal Cells that Injured by Oxygen-Glucose Deprivation/Reoxygenation Treatment Through Targeting TNFRSF1A and Regulating NF-κB Signaling Pathway. J Stroke Cerebrovasc Dis 2020;29:105210. [PMID: 33066952 DOI: 10.1016/j.jstrokecerebrovasdis.2020.105210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Qaiser H, Saeed M, Nerukh D, Ul-Haq Z. Structural insight into TNF-α inhibitors through combining pharmacophore-based virtual screening and molecular dynamic simulation. J Biomol Struct Dyn 2020;:1-20. [PMID: 32705954 DOI: 10.1080/07391102.2020.1796794] [Reference Citation Analysis]
23 Salvador-Martín S, Pujol-Muncunill G, Bossacoma F, Navas-López VM, Gallego-Fernández C, Segarra O, Clemente S, Muñoz-Codoceo R, Viada J, Magallares L, Martínez-Ojinaga E, Moreno-Álvarez A, Solar-Boga A, Loverdos I, Merino-Bohórquez V, Balboa-Vega MJ, Rodriguez-Martinez A, Alvarez-Vayo C, Sanchez C, Tolin M, Blanca-García JA, García-Romero R, Eizaguirre FJ, Sánchez-Hernandez JG, de Caldas RG, Millán-Jimenez A, Aznal E, Abarca-Zabalía J, Sanjurjo-Sáez M, López-Fernández LA. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease. Br J Clin Pharmacol 2021;87:447-57. [PMID: 32478906 DOI: 10.1111/bcp.14400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Endo K, Matsui R, Sugiyama M, Asami T, Inaba C, Kobayashi S, Makabe H, Tanaka S. Procyanidin B2 gallate regulates TNF-α production from T cells through inhibiting glycolytic activity via mTOR-HIF-1 pathway. Biochemical Pharmacology 2020;177:113952. [DOI: 10.1016/j.bcp.2020.113952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
25 Barra M, Danino T, Garrido D. Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases. Front Bioeng Biotechnol 2020;8:265. [PMID: 32296696 DOI: 10.3389/fbioe.2020.00265] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
26 Choi SY, Kang B, Choe YH. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease. Gut Liver 2019;13:541-8. [PMID: 30970435 DOI: 10.5009/gnl18129] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
27 Salvador-Martín S, López-Cauce B, Nuñez O, Laserna-Mendieta EJ, García MI, Lobato E, Abarca-Zabalía J, Sanjurjo-Saez M, Lucendo AJ, Marín-Jiménez I, Menchén LA, López-Fernández LA. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease. Pharmacol Res 2019;149:104478. [PMID: 31605784 DOI: 10.1016/j.phrs.2019.104478] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
28 Wajant H, Beilhack A. Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer. Front Immunol 2019;10:2040. [PMID: 31555271 DOI: 10.3389/fimmu.2019.02040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
29 Xu P, Elamin E, Elizalde M, Bours PPHA, Pierik MJ, Masclee AAM, Jonkers DMAE. Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model. Sci Rep 2019;9:2030. [PMID: 30765731 DOI: 10.1038/s41598-018-38322-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
30 Qasem A, Ramesh S, Naser SA. Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn's disease. BMJ Open Gastroenterol 2019;6:e000246. [PMID: 30815272 DOI: 10.1136/bmjgast-2018-000246] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
31 Gressner AM, Gressner OA. Tumornekrosefaktor-α. Springer Reference Medizin 2019. [DOI: 10.1007/978-3-662-48986-4_3136] [Reference Citation Analysis]
32 Aguiar FS, Mello FCDQ. Latent tuberculosis and the use of immunomodulatory agents. J bras pneumol 2019;45. [DOI: 10.1590/1806-3713/e20190361] [Reference Citation Analysis]
33 Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A, Papa A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018;19:E2199. [PMID: 30060508 DOI: 10.3390/ijms19082199] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
34 Fang L, Pang Z, Shu W, Wu W, Sun M, Cong Y, Liu Z. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease. Inflamm Bowel Dis 2018;24:1733-44. [PMID: 29718341 DOI: 10.1093/ibd/izy126] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
35 Wu Y, Ding J, Sun Q, Zhou K, Zhang W, Du Q, Xu T, Xu W. Long noncoding RNA hypoxia-inducible factor 1 alpha-antisense RNA 1 promotes tumor necrosis factor-α-induced apoptosis through caspase 3 in Kupffer cells. Medicine (Baltimore) 2018;97:e9483. [PMID: 29369172 DOI: 10.1097/MD.0000000000009483] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
36 Gressner AM, Gressner OA. Tumornekrosefaktor-α. Lexikon der Medizinischen Laboratoriumsdiagnostik 2018. [DOI: 10.1007/978-3-662-49054-9_3136-1] [Reference Citation Analysis]
37 Chemnitzer O, Götzel K, Maurer L, Dietrich A, Eichfeld U, Lyros O, Jansen-Winkeln B, Hoffmeister A, Gockel I, Thieme R. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus. Dig Dis Sci 2017;62:3391-401. [PMID: 29086334 DOI: 10.1007/s10620-017-4821-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
38 Golabi S, Zaringhalam J, Manaheji H. The Impact of Synovial NF-κB Activation on Apoptosis Pattern Change During Adjuvant-induced Inflammation. Basic Clin Neurosci 2017;8:173-82. [PMID: 28781725 DOI: 10.18869/nirp.bcn.8.3.173] [Reference Citation Analysis]
39 彭颖, 李晓波. 倍半萜内酯类治疗肠易激综合征的应用前景. 世界华人消化杂志 2017; 25(18): 1624-1632 [DOI: 10.11569/wcjd.v25.i18.1624] [Reference Citation Analysis]
40 Elhidaoui I. Neuropathie périphérique sous anti-TNF alpha au cours d’une rectocolite hémorragique : à propos d’un cas et revue de la littérature. J Afr Hepato Gastroenterol 2017;11:89-93. [DOI: 10.1007/s12157-017-0704-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Ilic B, Nikolic N, Andric M, Jelovac D, Milicic B, Jozic T, Krstic S, Milasin J. TNF-α (−308G>A) and TNF-R1 (36A>G) single nucleotide polymorphisms are strong risk factors for odontogenic keratocystic tumor development. J Oral Pathol Med 2017;46:292-6. [DOI: 10.1111/jop.12564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lie MR, Kreijne JE, van der Woude CJ. Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:75-81. [PMID: 28002127 DOI: 10.1097/MIB.0000000000000981] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
43 Silva FA, Rodrigues BL, Ayrizono ML, Leal RF. The Immunological Basis of Inflammatory Bowel Disease. Gastroenterol Res Pract. 2016;2016:2097274. [PMID: 28070181 DOI: 10.1155/2016/2097274] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 10.7] [Reference Citation Analysis]
44 Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses. J Cutan Med Surg 2003;7:382-6. [DOI: 10.1177/120347540300700503] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
45 Abreu MT, Thomas LS, Arnold ET, Lukasek K, Michelsen KS, Arditi M. TLR signaling at the intestinal epithelial interface. Journal of Endotoxin Research 2003;9:322-30. [DOI: 10.1177/09680519030090050901] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 12.4] [Reference Citation Analysis]
46 Cheng W, Tang C, Yin C. Effects of particle size and binding affinity for small interfering RNA on the cellular processing, intestinal permeation and anti-inflammatory efficacy of polymeric nanoparticles. J Gene Med 2015;17:244-56. [PMID: 26418829 DOI: 10.1002/jgm.2866] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
47 Li J, Kandatsu N, Feng GG, Jiang JZ, Huang L, Kinoshita H, Okada S, Fujiwara Y. Propofol reduces liver dysfunction caused by tumor necrosis factor-α production in Kupffer cells. J Anesth 2016;30:420-6. [PMID: 26882920 DOI: 10.1007/s00540-016-2145-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
48 Luchtefeld M, Jalouta T. Anal Fistula. Anorectal Disease 2016. [DOI: 10.1007/978-3-319-23147-1_6] [Reference Citation Analysis]
49 Salajegheh A. Tumour Necrosis Factor-α (TNF-α). Angiogenesis in Health, Disease and Malignancy 2016. [DOI: 10.1007/978-3-319-28140-7_56] [Reference Citation Analysis]
50 Allais L, Kumar S, Debusschere K, Verschuere S, Maes T, De Smet R, Conickx G, De Vos M, Laukens D, Joos GF, Brusselle GG, Elewaut D, Cuvelier CA, Bracke KR. The Effect of Cigarette Smoke Exposure on the Development of Inflammation in Lungs, Gut and Joints of TNFΔARE Mice. PLoS One 2015;10:e0141570. [PMID: 26523550 DOI: 10.1371/journal.pone.0141570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
51 Park KH, Yoon YD, Kang MR, Yun J, Oh SJ, Lee CW, Lee MY, Han SB, Kim Y, Kang JS. Hypothemycin inhibits tumor necrosis factor-α production by tristetraprolin-dependent down-regulation of mRNA stability in lipopolysaccharide-stimulated macrophages. Int Immunopharmacol 2015;29:863-8. [PMID: 26371861 DOI: 10.1016/j.intimp.2015.08.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Wu X, Chen H, Xu H. The genomic landscape of human immune-mediated diseases. J Hum Genet 2015;60:675-81. [PMID: 26290150 DOI: 10.1038/jhg.2015.99] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
53 Broekman MM, Roelofs HM, Hoentjen F, Wiegertjes R, Stoel N, Joosten LA, de Jong DJ, Wanten GJ. LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease. PLoS One 2015;10:e0133932. [PMID: 26208333 DOI: 10.1371/journal.pone.0133932] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
54 Chen W, Xu H, Wang X, Gu J, Xiong H, Shi Y. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis. Int Immunopharmacol 2015;28:146-53. [PMID: 26071216 DOI: 10.1016/j.intimp.2015.05.049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
55 Principi M, Day R, Marangi S, Burattini O, De Francesco V, Ingrosso M, Pisani A, Panella C, Forbes A, Di Leo A, Francavilla A, Ierardi E. Differential Immunohistochemical Expression of Syndecan-1 and Tumor Necrosis Factor Alpha in Colonic Mucosa of Patients with Crohn’s Disease. Immunopharmacology and Immunotoxicology 2015;28:185-95. [DOI: 10.1080/08923970600815048a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 Shen Z, Feng Y, Rickman B, Fox JG. Helicobacter cinaedi induced typhlocolitis in Rag-2-deficient mice. Helicobacter 2015;20:146-55. [PMID: 25381744 DOI: 10.1111/hel.12179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
57 Nakamizo S, Egawa G, Tomura M, Sakai S, Tsuchiya S, Kitoh A, Honda T, Otsuka A, Nakajima S, Dainichi T, Tanizaki H, Mitsuyama M, Sugimoto Y, Kawai K, Yoshikai Y, Miyachi Y, Kabashima K. Dermal Vγ4 + γδ T Cells Possess a Migratory Potency to the Draining Lymph Nodes and Modulate CD8 + T-Cell Activity through TNF-α Production. Journal of Investigative Dermatology 2015;135:1007-15. [DOI: 10.1038/jid.2014.516] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
58 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
59 Lie MR, Peppelenbosch MP, West RL, Zelinkova Z, van der Woude CJ. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment. Aliment Pharmacol Ther 2014;40:1202-8. [PMID: 25263077 DOI: 10.1111/apt.12969] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
60 Sloan S, Maxwell P, Salto-Tellez M, Loughrey MB. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab. Pathol Int 2014;64:624-7. [PMID: 25354875 DOI: 10.1111/pin.12219] [Reference Citation Analysis]
61 Chen G, Jiang L, Dong L, Wang Z, Xu F, Ding T, Fu L, Fang Q, Liu Z, Shan X, Liang G. Synthesis and biological evaluation of novel indole-2-one and 7-aza-2-oxindole derivatives as anti-inflammatory agents. Drug Des Devel Ther 2014;8:1869-92. [PMID: 25378906 DOI: 10.2147/DDDT.S65997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
62 Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs 2013;27:585-90. [PMID: 23749336 DOI: 10.1007/s40259-013-0045-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
63 Ebadi P, Daneshmandi S, Ghasemi A, Karimi MH. Cytokine single nucleotide polymorphisms in patients' with gallstone: dose TGF-β gene variants affect gallstone formation? Mol Biol Rep 2013;40:6256-60. [PMID: 24078093 DOI: 10.1007/s11033-013-2737-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Pallagi-Kunstár &, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 5031-5035 [PMID: 24833846 DOI: 10.3748/wjg.v20.i17.5031] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
65 Keshav S. Paneth Cells in Innate Immunity and Intestinal Inflammation. The Innate Immune Response to Infection 2014. [DOI: 10.1128/9781555817671.ch9] [Reference Citation Analysis]
66 Winsauer C, Kruglov AA, Chashchina AA, Drutskaya MS, Nedospasov SA. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine & Growth Factor Reviews 2014;25:115-23. [DOI: 10.1016/j.cytogfr.2013.12.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
67 Fontani F, Marcucci T, Picariello L, Tonelli F, Vincenzini MT, Iantomasi T. Redox regulation of MMP-3/TIMP-1 ratio in intestinal myofibroblasts: Effect of N-acetylcysteine and curcumin. Experimental Cell Research 2014;323:77-86. [DOI: 10.1016/j.yexcr.2014.02.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
68 Cockrell C, Christley S, An G. Investigation of inflammation and tissue patterning in the gut using a Spatially Explicit General-purpose Model of Enteric Tissue (SEGMEnT). PLoS Comput Biol 2014;10:e1003507. [PMID: 24675765 DOI: 10.1371/journal.pcbi.1003507] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
69 Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn’s disease with certolizumab pegol. Expert Review of Clinical Immunology 2014;3:683-94. [DOI: 10.1586/1744666x.3.5.683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
70 Yun L, Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;3:235-48. [DOI: 10.1586/egh.09.20] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
71 Papadakis KA. Adalimumab for the treatment of Crohn’s disease. Expert Review of Clinical Immunology 2014;2:11-5. [DOI: 10.1586/1744666x.2.1.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
72 Bradley GM, Oliva-hemker M. Infliximab for the treatment of pediatric ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;6:659-65. [DOI: 10.1586/egh.12.53] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini F, Salvarani C, Girolomoni G. The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. Int J Immunopathol Pharmacol 2014;27:1-10. [DOI: 10.1177/03946320140270s101] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
74 Liu M, Boussetta T, Makni-Maalej K, Fay M, Driss F, El-Benna J, Lagarde M, Guichardant M. Protectin DX, a double lipoxygenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities. Lipids 2014;49:49-57. [PMID: 24254970 DOI: 10.1007/s11745-013-3863-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
75 Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013;3:785-797. [PMID: 23720329 DOI: 10.1002/cphy.c120026] [Cited by in Crossref: 267] [Cited by in F6Publishing: 311] [Article Influence: 26.7] [Reference Citation Analysis]
76 Dhanani AS, Bagchi T. Lactobacillus plantarum CS24.2 prevents Escherichia coli adhesion to HT-29 cells and also down-regulates enteropathogen-induced tumor necrosis factor-α and interleukin-8 expression. Microbiol Immunol 2013;57:309-15. [PMID: 23586634 DOI: 10.1111/1348-0421.12038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
77 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602 [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 86] [Article Influence: 8.3] [Reference Citation Analysis]
78 Chiu YL, Rubin DT, Vermeire S, Louis E, Robinson AM, Lomax KG, Pollack PF, Paulson SK. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013;19:1112-22. [PMID: 23584130 DOI: 10.1097/MIB.0b013e3182813242] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 9.8] [Reference Citation Analysis]
79 Bilsborough J, Viney JL. From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease. Expert Opin Drug Discov 2006;1:69-83. [PMID: 23506033 DOI: 10.1517/17460441.1.1.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
80 Gressner AM, Arndt T. T. Lexikon der Medizinischen Laboratoriumsdiagnostik 2013. [DOI: 10.1007/978-3-642-12921-6_20] [Reference Citation Analysis]
81 Romagnoli C, Marcucci T, Picariello L, Tonelli F, Vincenzini MT, Iantomasi T. Role of N-acetylcysteine and GSH redox system on total and active MMP-2 in intestinal myofibroblasts of Crohn's disease patients. Int J Colorectal Dis 2013;28:915-24. [PMID: 23271497 DOI: 10.1007/s00384-012-1632-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
82 Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012; 18(37): 5219-5224 [PMID: 23066316 DOI: 10.3748/wjg.v18.i37.5219] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
83 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, Papa G, Gasbarrini A. Biological therapies for inflammatory bowel disease: controversies and future options. Expert Rev Clin Pharmacol. 2009;2:391-403. [PMID: 22112183 DOI: 10.1586/ecp.09.12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
84 Marticorena-Álvarez P, Chaparro M, Pérez-Casas A, Muriel-Herrero A, Gisbert JP. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease. J Crohns Colitis 2012;6:950-3. [PMID: 22537636 DOI: 10.1016/j.crohns.2012.03.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
85 Bermudez-Brito M, Muñoz-Quezada S, Gomez-Llorente C, Matencio E, Bernal MJ, Romero F, Gil A. Human intestinal dendritic cells decrease cytokine release against Salmonella infection in the presence of Lactobacillus paracasei upon TLR activation. PLoS One 2012;7:e43197. [PMID: 22905233 DOI: 10.1371/journal.pone.0043197] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 5.3] [Reference Citation Analysis]
86 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2012;18:1480-7. [PMID: 21987418 DOI: 10.1002/ibd.21886] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
87 Li XQ, Zhu YH, Zhang HF, Yue Y, Cai ZX, Lu QP, Zhang L, Weng XG, Zhang FJ, Zhou D, Yang JC, Wang JF. Risks associated with high-dose Lactobacillus rhamnosus in an Escherichia coli model of piglet diarrhoea: intestinal microbiota and immune imbalances. PLoS One 2012;7:e40666. [PMID: 22848393 DOI: 10.1371/journal.pone.0040666] [Cited by in Crossref: 91] [Cited by in F6Publishing: 96] [Article Influence: 8.3] [Reference Citation Analysis]
88 Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:971-86. [PMID: 22443153 DOI: 10.1111/j.1365-2036.2012.05057.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
89 Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011;5:679-84. [PMID: 22017695 DOI: 10.1586/egh.11.81] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
90 Bultman E, de Haar C, van Liere-Baron A, Verhoog H, West RL, Kuipers EJ, Zelinkova Z, van der Woude CJ. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012;35:335-41. [PMID: 22191671 DOI: 10.1111/j.1365-2036.2011.04946.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
91 Mouzaoui S, Rahim I, Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice. Int Immunopharmacol. 2012;12:302-311. [PMID: 22036766 DOI: 10.1016/j.intimp.2011.10.010] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
92 Luna T, Santos SB, Nascimento M, Porto MA, Muniz AL, Carvalho EM, Jesus AR. Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Braz J Med Biol Res 2011;44:1134-40. [PMID: 22011961 DOI: 10.1590/s0100-879x2011007500140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
93 Barollo M, Medici V, D’Incà R, Banerjee A, Ingravallo G, Scarpa M, Patak S, Ruffolo C, Cardin R, Sturniolo GC. Antioxidative potential of a combined therapy of anti TNFα and Zn acetate in experimental colitis. World J Gastroenterol 2011; 17(36): 4099-4103 [PMID: 22039323 DOI: 10.3748/wjg.v17.i36.4099] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
94 Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:221-33. [PMID: 16901386 DOI: 10.1007/s11938-006-0041-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
95 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
96 Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008;2:763-777. [PMID: 19707457 DOI: 10.2147/btt.s3292] [Cited by in Crossref: 7] [Cited by in F6Publishing: 22] [Article Influence: 0.6] [Reference Citation Analysis]
97 Lim AW, Panaccione R, Seow CH. Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease. Therap Adv Gastroenterol 2011;4:145-51. [PMID: 21694815 DOI: 10.1177/1756283X10382816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
98 Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007;10:195-207. [PMID: 17547858 DOI: 10.1007/s11938-007-0013-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
99 Gioxari A, Kaliora AC, Papalois A, Agrogiannis G, Triantafillidis JK, Andrikopoulos NK. Pistacia lentiscus resin regulates intestinal damage and inflammation in trinitrobenzene sulfonic acid-induced colitis. J Med Food 2011;14:1403-11. [PMID: 21612460 DOI: 10.1089/jmf.2010.0240] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
100 Cohen JI, Chen X, Nagy LE. Redox signaling and the innate immune system in alcoholic liver disease. Antioxid Redox Signal. 2011;15:523-534. [PMID: 21126203 DOI: 10.1089/ars.2010.3746] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
101 Karmiris K, Bielen D, Vanbeckevoort D, Vermeire S, Coremans G, Rutgeerts P, Van Assche G. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011;9:130-6. [PMID: 21056696 DOI: 10.1016/j.cgh.2010.10.022] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 6.3] [Reference Citation Analysis]
102 Bamias G, Pizarro T, Cominelli F. New Paradigms in the Pathogenesis of IBD. Inflammatory Bowel Disease 2011. [DOI: 10.1007/978-1-60327-433-3_4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, Hrncir T, Rossmann P, Mrazek J, Kopecny J, Verdu EF, Tlaskalova-Hogenova H. Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol. 2011;163:250-259. [PMID: 21087444 DOI: 10.1111/j.1365-2249.2010.04286.x] [Cited by in Crossref: 189] [Cited by in F6Publishing: 199] [Article Influence: 14.5] [Reference Citation Analysis]
104 Di Sabatino A, Biancheri P, Piconese S, Rosado MM, Ardizzone S, Rovedatti L, Ubezio C, Massari A, Sampietro GM, Foschi D, Porro GB, Colombo MP, Carsetti R, MacDonald TT, Corazza GR. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:1891-7. [PMID: 20848485 DOI: 10.1002/ibd.21271] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
105 Lacher M, Fitze G, Helmbrecht J, Schroepf S, Berger M, Lohse P, Koletzko S, Ballauff A, Grote V, Goedeke J, von Schweinitz D, Kappler R. Hirschsprung-associated enterocolitis develops independently of NOD2 variants. Journal of Pediatric Surgery 2010;45:1826-31. [DOI: 10.1016/j.jpedsurg.2010.02.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
106 Yang YY, Liu H, Nam SW, Kunos G, Lee SS. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 2010;53:298-306. [PMID: 20626112 DOI: 10.1016/j.jhep.2010.03.011] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
107 Werno C, Schmid T, Schnitzer SE, Peters K, Milke L, Brüne B. A combination of hypoxia and lipopolysaccharide activates tristetraprolin to destabilize proinflammatory mRNAs such as tumor necrosis factor-alpha. Am J Pathol 2010;177:1104-12. [PMID: 20639458 DOI: 10.2353/ajpath.2010.091212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
108 Nguyen-Khac E, Houchi H, Daoust M, Dupas JL, Naassila M. Lack of association between tumour necrosis factor receptor types 1 and 2 gene polymorphism and severe acute alcoholic hepatitis. Eur J Gastroenterol Hepatol 2010;22:794-800. [PMID: 19641466 DOI: 10.1097/MEG.0b013e32832f5bba] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
109 Vilela MC, Lima GK, Rodrigues DH, Lacerda-queiroz N, Mansur DS, Miranda ASD, Rachid MA, Kroon EG, Vieira LQ, Campos MA, Teixeira MM, Teixeira AL. TNFR1 plays a critical role in the control of severe HSV-1 encephalitis. Neuroscience Letters 2010;479:58-62. [DOI: 10.1016/j.neulet.2010.05.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
110 Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010;16:962-73. [PMID: 19821509 DOI: 10.1002/ibd.21117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 95] [Article Influence: 7.4] [Reference Citation Analysis]
111 Mandal P, Pritchard MT, Nagy LE. Anti-inflammatory pathways and alcoholic liver disease: Role of an adiponectin/interleukin-10/heme oxygenase-1 pathway. World J Gastroenterol 2010; 16(11): 1330-1336 [PMID: 20238399 DOI: 10.3748/wjg.v16.i11.1330] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 79] [Article Influence: 5.5] [Reference Citation Analysis]
112 Mulay SR, Gaikwad AB, Tikoo K. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Chem Biol Interact. 2010;185:137-142. [PMID: 20223228 DOI: 10.1016/j.cbi.2010.03.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
113 Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol 2010;22:334-9. [PMID: 19528808 DOI: 10.1097/MEG.0b013e32832b20d4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
114 Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC. Mechanisms and Efficacy of Immunobiologic Therapies for Inflammatory Bowel Diseases. International Reviews of Immunology 2010;29:4-37. [DOI: 10.3109/08830180903437212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
115 Seror R, Pagnoux C. Biothérapies et anticorps monoclonaux. Les Uvéites 2010. [DOI: 10.1016/b978-2-294-71107-7.50059-7] [Reference Citation Analysis]
116 Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010;3:49-56. [PMID: 19794409 DOI: 10.1038/mi.2009.116] [Cited by in Crossref: 187] [Cited by in F6Publishing: 191] [Article Influence: 14.4] [Reference Citation Analysis]
117 Kotlyar DS, Blonski WC, Lichtenstein GR. Advances in Understanding the Pathogenesis of Inflammatory Bowel Disease. Handbook of Cell Signaling 2010. [DOI: 10.1016/b978-0-12-374145-5.00338-7] [Reference Citation Analysis]
118 Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA. 2010;107:454-459. [PMID: 20018654 DOI: 10.1073/pnas.0910307107] [Cited by in Crossref: 242] [Cited by in F6Publishing: 251] [Article Influence: 17.3] [Reference Citation Analysis]
119 Poturoglu S, Kaymakoglu S, Gurel Polat N, Ibrisim D, Ahishali E, Akyuz F, Badur S, Demir K, Mungan Z. A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease. Scand J Clin Lab Invest 2009;69:696-702. [PMID: 19452347 DOI: 10.3109/00365510902989075] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
120 Choi SW, Ahn JJ, Hwang YT, Koh SH, Cho SD. A case of tuberculous arthritis following the use of etanercept. Korean J Intern Med 2009;24:397-401. [PMID: 19949742 DOI: 10.3904/kjim.2009.24.4.397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
121 Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40. [PMID: 19664627 DOI: 10.1053/j.gastro.2009.07.062] [Cited by in Crossref: 378] [Cited by in F6Publishing: 397] [Article Influence: 27.0] [Reference Citation Analysis]
122 Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727-35. [PMID: 19294580 DOI: 10.1080/00365520902803507] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
123 Kono H, Fujii H, Ishii K, Hosomura N, Ogiku M. Dietary medium-chain triglycerides prevent chemically induced experimental colitis in rats. Transl Res 2010;155:131-41. [PMID: 20171598 DOI: 10.1016/j.trsl.2009.08.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
124 Zhang MM, Jiang M. Advances in the pathogenesis of irritable bowel syndrome. Shijie Huaren Xiaohua Zazhi 2009; 17(24): 2484-2490 [DOI: 10.11569/wcjd.v17.i24.2484] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
125 Boussetta T, Raad H, Lettéron P, Gougerot-Pocidalo MA, Marie JC, Driss F, El-Benna J. Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. PLoS One. 2009;4:e6458. [PMID: 19649246 DOI: 10.1371/journal.pone.0006458] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 5.7] [Reference Citation Analysis]
126 Ait-Ali D, Stroth N, Sen JM, Eiden LE. PACAP-cytokine interactions govern adrenal neuropeptide biosynthesis after systemic administration of LPS. Neuropharmacology 2010;58:208-14. [PMID: 19647754 DOI: 10.1016/j.neuropharm.2009.07.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
127 Mazzon E, Esposito E, Di Paola R, Riccardi L, Caminiti R, Dal Toso R, Pressi G, Cuzzocrea S. Effects of verbascoside biotechnologically produced by Syringa vulgaris plant cell cultures in a rodent model of colitis. Naunyn Schmiedebergs Arch Pharmacol. 2009;380:79-94. [PMID: 19242677 DOI: 10.1007/s00210-009-0400-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
128 Taweechotipatr M, Iyer C, Spinler JK, Versalovic J, Tumwasorn S. Lactobacillus saerimneri and Lactobacillus ruminis: novel human-derived probiotic strains with immunomodulatory activities. FEMS Microbiol Lett 2009;293:65-72. [PMID: 19222575 DOI: 10.1111/j.1574-6968.2009.01506.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
129 Lionaki S, Siamopoulos K, Theodorou I, Papadimitraki E, Bertsias G, Boumpas D, Boletis J. Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrology Dialysis Transplantation 2009;24:2144-50. [DOI: 10.1093/ndt/gfn771] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
130 Feldman TL, Rosh JR. Infliximab in the treatment of pediatric Crohn’s disease. Therapy 2009;6:15-22. [DOI: 10.2217/14750708.6.1.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
131 Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1683-7. [PMID: 18618629 DOI: 10.1002/ibd.20534] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
132 Wei X, Gong J, Zhu J, Niu L, Zhu W, Li N, Li J. Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis. International Immunopharmacology 2008;8:1808-12. [DOI: 10.1016/j.intimp.2008.08.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
133 Laerum OD, Illemann M, Skarstein A, Helgeland L, Ovrebø K, Danø K, Nielsen BS. Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons. Am J Gastroenterol 2008;103:2350-8. [PMID: 18844621 DOI: 10.1111/j.1572-0241.2008.01930.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
134 Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. Journal of the American Academy of Dermatology 2008;59:363-80. [DOI: 10.1016/j.jaad.2008.05.033] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
135 Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 2008;14:1068-83. [PMID: 18425802 DOI: 10.1002/ibd.20448] [Cited by in Crossref: 161] [Cited by in F6Publishing: 165] [Article Influence: 10.7] [Reference Citation Analysis]
136 Lakatos PL, Lakatos L. Anti-TNF-α therapy in ulcerative colitis. Orvosi Hetilap 2008;149:921-927. [DOI: 10.1556/oh.2008.28360] [Reference Citation Analysis]
137 Matsukura H, Ikeda S, Yoshimura N, Takazoe M, Muramatsu M. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther 2008;27:765-70. [PMID: 18248655 DOI: 10.1111/j.1365-2036.2008.03630.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
138 Ribeiro de Jesus A, Luna T, Pacheco de Almeida R, Machado PR, Carvalho EM. Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections. Int Immunopharmacol. 2008;8:1344-1353. [PMID: 18687297 DOI: 10.1016/j.intimp.2008.03.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
139 Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn’s disease. Immunology. 2008;125:178-183. [PMID: 18422560 DOI: 10.1111/j.1365-2567.2008.02839.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 5.5] [Reference Citation Analysis]
140 Williams GM. Antitumor necrosis factor-α therapy and potential cancer inhibition. European Journal of Cancer Prevention 2008;17:169-77. [DOI: 10.1097/cej.0b013e3282b6fcff] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
141 Mizoguchi E, Hachiya Y, Kawada M, Nagatani K, Ogawa A, Sugimoto K, Mizoguchi A, Podolsky DK. TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. Gastroenterology 2008;134:470-80. [PMID: 18242213 DOI: 10.1053/j.gastro.2007.11.055] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
142 Jilani NZ, Akobeng AK. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Colombel JF, Sandborn WJ, Rutgeerts P et al. Gastroenterology 2007;132:52-65. J Pediatr Gastroenterol Nutr 2008;46:226-7. [PMID: 18223389 DOI: 10.1097/MPG.0b013e318156e139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
143 Saeed SA, Crandall WV. Managing Crohn Disease in Children and Adolescents: Focus on Tumor Necrosis Factor Antagonists. Pediatric Drugs 2008;10:31-8. [DOI: 10.2165/00148581-200810010-00004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
144 Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opinion on Biological Therapy 2007;7:1869-80. [DOI: 10.1517/14712598.7.12.1869] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
145 Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, Florholmen J. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 2007;42:1312-20. [PMID: 17852866 DOI: 10.1080/00365520701409035] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 6.0] [Reference Citation Analysis]
146 Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9. [PMID: 17299059 DOI: 10.1136/gut.2006.106781] [Cited by in Crossref: 703] [Cited by in F6Publishing: 514] [Article Influence: 43.9] [Reference Citation Analysis]
147 Rojas-villarraga A, Agudelo CA, Pineda-tamayo R, Porras A, Matute G, Anaya JM. Tuberculosis en pacientes tratados con antagonistas del factor de necrosis tumoral alfa en un área endémica, ¿vale la pena el riesgo? biomedica 2007;27:159. [DOI: 10.7705/biomedica.v27i2.212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
148 Kohno H, Takahashi M, Yasui Y, Suzuki R, Miyamoto S, Kamanaka Y, Naka M, Maruyama T, Wakabayashi K, Tanaka T. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc(Min/+) mice. Int J Cancer 2007;121:506-13. [PMID: 17417780 DOI: 10.1002/ijc.22736] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
149 Salfeld J, Kupper H. Adalimumab. Biologics in General Medicine. [DOI: 10.1007/978-3-540-29018-6_3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
150 Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opinion on Biological Therapy 2007;7:1051-9. [DOI: 10.1517/14712598.7.7.1051] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
151 Bates RC, Pursell BM, Mercurio AM. Epithelial-Mesenchymal Transition and Colorectal Cancer: Gaining Insights into Tumor Progression Using LIM 1863 Cells. Cells Tissues Organs 2007;185:29-39. [DOI: 10.1159/000101300] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
152 Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm Bowel Dis 2007;13:769-96. [PMID: 17304581 DOI: 10.1002/ibd.20027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
153 Gao Q, Meijer MJ, Schlüter UG, van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB, Verspaget HW. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 2007;13:693-702. [PMID: 17243139 DOI: 10.1002/ibd.20100] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
154 Qiu L, Yoshida K, Amorim BR, Okamura H, Haneji T. Calyculin A stimulates the expression of TNF-α mRNA via phosphorylation of Akt in mouse osteoblastic MC3T3-E1 cells. Molecular and Cellular Endocrinology 2007;271:38-44. [DOI: 10.1016/j.mce.2007.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
155 Thakur V, McMullen MR, Pritchard MT, Nagy LE. Regulation of macrophage activation in alcoholic liver disease. J Gastroenterol Hepatol 2007;22 Suppl 1:S53-6. [PMID: 17567466 DOI: 10.1111/j.1440-1746.2006.04650.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 4.4] [Reference Citation Analysis]
156 Duggan A. Are biologicals safe enough? Falk Symposium. [DOI: 10.1007/978-1-4020-5702-1_28] [Reference Citation Analysis]
157 Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007;56:509-17. [PMID: 17082252 DOI: 10.1136/gut.2006.105379] [Cited by in Crossref: 129] [Cited by in F6Publishing: 118] [Article Influence: 8.1] [Reference Citation Analysis]
158 Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007;25:787-96. [PMID: 17373917 DOI: 10.1111/j.1365-2036.2007.03253.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
159 Cytokine-Mediated Toxicity. Mechanistic Toxicology 2007. [DOI: 10.1201/b14259-13] [Reference Citation Analysis]
160 Mazzon E, Esposito E, Crisafulli C, Riccardi L, Muià C, Di Bella P, Meli R, Cuzzocrea S. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res. 2006;41:363-373. [PMID: 17014694 DOI: 10.1111/j.1600-079x.2006.00378.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 3.7] [Reference Citation Analysis]
161 Takai S, Nagaki M, Imao M, Kimura K, Kozawa O, Moriwaki H. Intrinsic resistance to TNF-α-induced hepatocyte apoptosis in ICR mice correlates with expression of a short form of c-FLIP. Lab Invest 2007;87:572-81. [DOI: 10.1038/labinvest.3700544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
162 Frulloni L, Bernardoni L, Scattolini C, Vantini I. Biological Approach in the Treatment of Crohn’s Disease. Inflammatory Bowel Disease and Familial Adenomatous Polyposis. [DOI: 10.1007/88-470-0434-9_16] [Reference Citation Analysis]
163 Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602-610. [PMID: 17075599 DOI: 10.1038/ncprheum0336] [Cited by in Crossref: 204] [Cited by in F6Publishing: 216] [Article Influence: 12.8] [Reference Citation Analysis]
164 Karger R, Weber C, Schmidt J, Kretschmer V. Characterization of immune system alterations following preoperative autologous blood donation for elective hip replacement surgery. Transfusion Medicine 2007;17:45-53. [DOI: 10.1111/j.1365-3148.2006.00711.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
165 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
166 Gressner AM, Arndt T. T. Lexikon der Medizinischen Laboratoriumsdiagnostik 2007. [DOI: 10.1007/978-3-540-49520-8_20] [Reference Citation Analysis]
167 Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041] [Cited by in Crossref: 1583] [Cited by in F6Publishing: 1665] [Article Influence: 98.9] [Reference Citation Analysis]
168 Richter JA, Bickston SJ. Infliximab use in luminal Crohn's disease. Gastroenterol Clin North Am 2006;35:775-93. [PMID: 17129813 DOI: 10.1016/j.gtc.2006.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
169 Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, Schmitz-Madry A, Zahn A, Stremmel W, Schmitz G. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl). 2006;84:1055-1066. [PMID: 17058067 DOI: 10.1007/s00109-006-0100-2] [Cited by in Crossref: 116] [Cited by in F6Publishing: 117] [Article Influence: 6.8] [Reference Citation Analysis]
170 el-Marjou A, Delouvée A, Thiery JP, Radvanyi F. Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis. 2000;21:2211-2218. [PMID: 17058067 DOI: 10.1093/carcin/21.12.2211] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
171 Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 2006;119:639-46. [PMID: 16887405 DOI: 10.1016/j.amjmed.2006.01.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 2.7] [Reference Citation Analysis]
172 Zhi L, Leung BP, Melendez AJ. Sphingosine kinase 1 regulates pro-inflammatory responses triggered by TNFalpha in primary human monocytes. J Cell Physiol 2006;208:109-15. [PMID: 16575915 DOI: 10.1002/jcp.20646] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 3.2] [Reference Citation Analysis]
173 Seitz G, Warmann SW, Guglielmetti A, Heitmann H, Ruck P, Kreis ME, Fuchs J. Protective effect of tumor necrosis factor alpha antibody on experimental necrotizing enterocolitis in the rat. J Pediatr Surg. 2005;40:1440-1445. [PMID: 16150346 DOI: 10.1016/j.jpedsurg.2005.05.043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
174 García de Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M. Distinctive pattern of cytokine production and adhesion molecule expression in peripheral blood memory CD4+ T cells from patients with active Crohn's disease. J Clin Immunol 2006;26:233-42. [PMID: 16783463 DOI: 10.1007/s10875-006-9016-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
175 Chen MC, Mudge CS, Klumpp DJ. Urothelial lesion formation is mediated by TNFR1 during neurogenic cystitis. Am J Physiol Renal Physiol 2006;291:F741-9. [PMID: 16622179 DOI: 10.1152/ajprenal.00081.2006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
176 Chang JT, Lichtenstein GR. Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2006;3:220-8. [DOI: 10.1038/ncpgasthep0447] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
177 Otani T, Yamaguchi K, Scherl E, Du B, Tai HH, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K, Dannenberg AJ. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am J Physiol Gastrointest Liver Physiol 2006;290:G361-8. [PMID: 16195422 DOI: 10.1152/ajpgi.00348.2005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 3.2] [Reference Citation Analysis]
178 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591. [PMID: 16472588 DOI: 10.1053/j.gastro.2005.11.030] [Cited by in Crossref: 1143] [Cited by in F6Publishing: 1232] [Article Influence: 67.2] [Reference Citation Analysis]
179 Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 2006;22:30-43. [PMID: 16319674 DOI: 10.1097/01.mog.0000196151.74819.8e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
180 Yokoyama K, Nakajima N, Ito Y, Iwasaki A, Arakawa Y. Histoimmunological Evaluation for the Efficacy of Entero Nutrient Containing n-3 Fatty Acids in TNBS Rat Colitis Model. J Clin Biochem Nutr 2006;39:88-97. [DOI: 10.3164/jcbn.39.88] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
181 Mccartney S, Farthing MJ. Advances in the Medical Treatment of Crohn’s Disease. Progress in Colorectal Surgery. [DOI: 10.1007/1-84628-058-3_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Mufti AH, Toye BW, Mckendry RR, Angel JB. Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use. Diagnostic Microbiology and Infectious Disease 2005;53:233-8. [DOI: 10.1016/j.diagmicrobio.2005.06.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
183 Rojas-cartagena C, Flores I, Appleyard CB. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine 2005;32:85-93. [DOI: 10.1016/j.cyto.2005.08.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.3] [Reference Citation Analysis]
184 Schwartz S, Beaulieu JF, Ruemmele FM. Interleukin-17 is a potent immuno-modulator and regulator of normal human intestinal epithelial cell growth. Biochem Biophys Res Commun. 2005;337:505-509. [PMID: 16198312 DOI: 10.1016/j.bbrc.2005.09.075] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
185 Stokkers PC, Hommes DW. New cytokine therapeutics for inflammatory bowel disease. Cytokine. 2004;28:167-173. [PMID: 15588691 DOI: 10.1016/j.cyto.2004.07.012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 3.1] [Reference Citation Analysis]
186 Ahn DH, Crawley SC, Hokari R, Kato S, Yang SC, Li JD, Kim YS. TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation. Cell Physiol Biochem. 2005;15:29-40. [PMID: 15665513 DOI: 10.1159/000083636] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 3.3] [Reference Citation Analysis]
187 Viscido A, Aratari A, Maccioni F, Signore A, Caprilli R. Inflammatory bowel diseases: clinical update of practical guidelines. Nuclear Medicine Communications 2005;26:649-55. [DOI: 10.1097/01.mnm.0000169205.21377.6a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
188 Wang J, Anders RA, Wang Y, Turner JR, Abraham C, Pfeffer K, Fu Y. The Critical Role of LIGHT in Promoting Intestinal Inflammation and Crohn’s Disease. J Immunol 2005;174:8173-82. [DOI: 10.4049/jimmunol.174.12.8173] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 3.8] [Reference Citation Analysis]
189 Dai Q, Zhang J, Pruett SB. Ethanol alters cellular activation and CD14 partitioning in lipid rafts. Biochemical and Biophysical Research Communications 2005;332:37-42. [DOI: 10.1016/j.bbrc.2005.04.088] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 3.6] [Reference Citation Analysis]
190 McMullen MR, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE. Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice. Gastroenterology 2005;128:2066-76. [PMID: 15940638 DOI: 10.1053/j.gastro.2005.02.065] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 4.4] [Reference Citation Analysis]
191 Waschke KA, Villani AC, Vermeire S, Dufresne L, Chen TC, Bitton A, Cohen A, Thomson AB, Wild GE. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol 2005;100:1126-33. [PMID: 15842589 DOI: 10.1111/j.1572-0241.2005.40534.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
192 Hassan C, Zullo A, Campo SM, Morini S. New insights into the biological therapy of Crohn’s disease. Expert Opinion on Therapeutic Patents 2005;15:409-19. [DOI: 10.1517/13543776.15.4.409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
193 Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 2005;39:303-6. [PMID: 15758624 DOI: 10.1097/01.mcg.0000155126.82171.32] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
194 Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, Murakami T, Drutskaya LN, Förster I, Clausen BE, Tessarollo L, Ryffel B, Kuprash DV, Nedospasov SA. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 2005;22:93-104. [PMID: 15664162 DOI: 10.1016/j.immuni.2004.11.016] [Cited by in Crossref: 71] [Cited by in F6Publishing: 161] [Article Influence: 3.9] [Reference Citation Analysis]
195 Cuzzocrea S. Emerging biotherapies for inflammatory bowel disease. Expert Opinion on Emerging Drugs 2005;8:339-47. [DOI: 10.1517/14728214.8.2.339] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
196 Bernstein CN. Novel therapeutics in inflammatory bowel disease. Expert Opinion on Therapeutic Patents 2005;11:1081-96. [DOI: 10.1517/13543776.11.7.1081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
197 Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 191] [Cited by in F6Publishing: 206] [Article Influence: 10.6] [Reference Citation Analysis]
198 Takei Y, Enomoto N, Ikejima K, Yamashina S, Kitamura T, Sato N. Roles of Kupffer Cells in Alcoholic Liver Disease. Comprehensive Handbook of Alcohol Related Pathology 2005. [DOI: 10.1016/b978-012564370-2/50060-x] [Reference Citation Analysis]
199 Baidoo L, Lichtenstein GR. What next after infliximab? Am J Gastroenterol 2005;100:80-3. [PMID: 15654785 DOI: 10.1111/j.1572-0241.2005.41716.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
200 Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;100:75-9. [PMID: 15654784 DOI: 10.1111/j.1572-0241.2005.40647.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 117] [Article Influence: 6.4] [Reference Citation Analysis]
201 Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, Martin A, Guimont MC, Cazals-Hatem D, Lebrec D. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats. Gut 2004;53:1844-9. [PMID: 15542526 DOI: 10.1136/gut.2003.036517] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
202 Cao W, Cheng L, Behar J, Fiocchi C, Biancani P, Harnett KM. Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol 2004;287:G1131-9. [PMID: 15271650 DOI: 10.1152/ajpgi.00216.2004] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 3.5] [Reference Citation Analysis]
203 Imose M, Nagaki M, Kimura K, Takai S, Imao M, Naiki T, Osawa Y, Asano T, Hayashi H, Moriwaki H. Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappaB. Hepatology 2004;40:1160-9. [PMID: 15455409 DOI: 10.1002/hep.20438] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
204 Bates RC, DeLeo MJ 3rd, Mercurio AM. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 2004;299:315-24. [PMID: 15350531 DOI: 10.1016/j.yexcr.2004.05.033] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 5.4] [Reference Citation Analysis]
205 Balog A, Klausz G, Gál J, Molnár T, Nagy F, Ocsovszky I, Gyulai Z, Mándi Y. Investigation of the Prognostic Value of TNF-α Gene Polymorphism among Patients Treated with Infliximab, and the Effects of Infliximab Therapy on TNF-α Production and Apoptosis. Pathobiology 2004;71:274-80. [DOI: 10.1159/000080062] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
206 Cuzzocrea S, Mazzon E, Di Paola R, Patel NS, Genovese T, Muià C, De Sarro A, Thiemermann C. Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther. 2004;311:1272-1280. [PMID: 15302898 DOI: 10.1124/jpet.104.073197] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 2.1] [Reference Citation Analysis]
207 Spahr L, Giostra E, Frossard JL, Bresson-Hadni S, Rubbia-Brandt L, Hadengue A. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol 2004;41:229-34. [PMID: 15288471 DOI: 10.1016/j.jhep.2004.04.028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 2.6] [Reference Citation Analysis]
208 Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 2004;39:203-6. [PMID: 15269630 DOI: 10.1097/00005176-200408000-00016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
209 Nagy LE. Stabilization of tumor necrosis factor-alpha mRNA in macrophages in response to chronic ethanol exposure. Alcohol 2004;33:229-33. [PMID: 15596091 DOI: 10.1016/j.alcohol.2004.09.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
210 Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004;:CD003574. [PMID: 14974022 DOI: 10.1002/14651858.CD003574.pub2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 59] [Article Influence: 1.5] [Reference Citation Analysis]
211 Sobkeng Goufack E, Mammou S, Scotto B, De Muret A, Maakaroun A, Socie G, Bacq Y. Thrombose des veines hépatiques au cours d’un traitement par infliximab (Remicade®) révélant une hémoglobinurie paroxystique nocturne. Gastroentérologie Clinique et Biologique 2004;28:596-9. [DOI: 10.1016/s0399-8320(04)95017-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
212 Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7. [PMID: 15191204 DOI: 10.1016/j.dld.2003.12.014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 6.1] [Reference Citation Analysis]
213 Thwin MM, Douni E, Aidinis V, Kollias G, Kodama K, Sato K, Satish RL, Mahendran R, Gopalakrishnakone P. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res Ther 2004;6:R282-94. [PMID: 15142275 DOI: 10.1186/ar1179] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
214 Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13. [PMID: 15067625 DOI: 10.1016/s1542-3565(04)00060-6] [Cited by in Crossref: 125] [Cited by in F6Publishing: 131] [Article Influence: 6.6] [Reference Citation Analysis]
215 Thorn CF, Lu ZY, Whitehead AS. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol. 2004;59:152-158. [PMID: 14871291 DOI: 10.1111/j.0300-9475.2004.01369.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 3.2] [Reference Citation Analysis]
216 Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004;10:91-6. [PMID: 15168807 DOI: 10.1097/00054725-200403000-00005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
217 Kirkegaard T, Pedersen G, Saermark T, Brynskov J. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol 2004;135:146-53. [PMID: 14678276 DOI: 10.1111/j.1365-2249.2004.02348.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
218 Pizarro TT, Arseneau KO, Bamias G, Cominelli F. Mouse models for the study of Crohn's disease. Trends Mol Med 2003;9:218-22. [PMID: 12763527 DOI: 10.1016/s1471-4914(03)00052-2] [Cited by in Crossref: 121] [Cited by in F6Publishing: 113] [Article Influence: 6.4] [Reference Citation Analysis]
219 Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 2004;10 Suppl 1:S38-43. [PMID: 15168830 DOI: 10.1097/00054725-200402001-00009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
220 Enomoto N, Takei Y, Hirose M, Ikejima K, Kitamura T, Sato N. Thalidomide Prevents Alcoholic Liver Injury in Rats Through Inhibition of Kupffer Cell Sensitization. Comp Hepatol 2004;3 Suppl 1:S37. [PMID: 14960189 DOI: 10.1186/1476-5926-2-S1-S37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
221 Kishore R, McMullen MR, Cocuzzi E, Nagy LE. Lipopolysaccharide-mediated signal transduction: Stabilization of TNF-alpha mRNA contributes to increased lipopolysaccharide-stimulated TNF-alpha production by Kupffer cells after chronic ethanol feeding. Comp Hepatol 2004;3 Suppl 1:S31. [PMID: 14960183 DOI: 10.1186/1476-5926-2-S1-S31] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
222 Veljača M. Pharmacotherapy of inflammatory bowel disease: Novel therapeutic approaches. Pharmacotherapy of Gastrointestinal Inflammation 2004. [DOI: 10.1007/978-3-0348-7930-9_2] [Reference Citation Analysis]
223 Brookes MJ, Green JRB. Maintenance of Remission in Crohn???s Disease: Current and Emerging Therapeutic Options. Drugs 2004;64:1069-89. [DOI: 10.2165/00003495-200464100-00004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
224 Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004;53:70-7. [PMID: 14684579 DOI: 10.1136/gut.53.1.70] [Cited by in Crossref: 130] [Cited by in F6Publishing: 119] [Article Influence: 6.8] [Reference Citation Analysis]
225 Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62 Suppl 2:ii37-42. [PMID: 14532147 DOI: 10.1136/ard.62.suppl_2.ii37] [Cited by in Crossref: 35] [Cited by in F6Publishing: 56] [Article Influence: 1.8] [Reference Citation Analysis]
226 Sanchez AL, Langdon CM, Akhtar M, Lu J, Richards CD, Bercik P, McKay DM. Adenoviral transfer of the murine oncostatin M gene suppresses dextran-sodium sulfate-induced colitis. J Interferon Cytokine Res 2003;23:193-201. [PMID: 12856331 DOI: 10.1089/107999003765027393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
227 Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn’s disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003;47:1-10. [PMID: 12526855 DOI: 10.1016/s1043-6618(02)00264-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
228 Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003;18:741-7. [PMID: 14510748 DOI: 10.1046/j.1365-2036.2003.01739.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
229 Tsune I, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Takei Y, Sato N. Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology 2003;125:775-85. [PMID: 12949723 DOI: 10.1016/s0016-5085(03)01067-9] [Cited by in Crossref: 105] [Cited by in F6Publishing: 110] [Article Influence: 5.3] [Reference Citation Analysis]
230 Genescà J, Martí R, Rojo F, Campos F, Peribáñez V, Gónzalez A, Castells L, Ruiz-Marcellán C, Margarit C, Esteban R, Guardia J, Segura R. Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut 2003;52:1054-9. [PMID: 12801966 DOI: 10.1136/gut.52.7.1054] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 2.7] [Reference Citation Analysis]
231 Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, Cominelli F. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 2003;100:8366-8371. [PMID: 12832622 DOI: 10.1073/pnas.1432897100] [Cited by in Crossref: 152] [Cited by in F6Publishing: 162] [Article Influence: 7.6] [Reference Citation Analysis]
232 Enomoto N, Takei Y, Hirose M, Konno A, Shibuya T, Matsuyama S, Suzuki S, Kitamura KI, Sato N. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther. 2003;306:846-854. [PMID: 12805475 DOI: 10.1124/jpet.102.047217] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 4.1] [Reference Citation Analysis]
233 Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85. [PMID: 12806611 DOI: 10.1016/s0016-5085(03)00382-2] [Cited by in Crossref: 543] [Cited by in F6Publishing: 569] [Article Influence: 27.2] [Reference Citation Analysis]
234 Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. [PMID: 12614731 DOI: 10.1016/s1473-3099(03)00545-0] [Cited by in Crossref: 511] [Cited by in F6Publishing: 446] [Article Influence: 25.6] [Reference Citation Analysis]
235 Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med. 2002;252:475-496. [PMID: 12472908 DOI: 10.1046/j.1365-2796.2002.01067.x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 132] [Article Influence: 5.9] [Reference Citation Analysis]
236 Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T, Kotlyarov A, Forster I, Flavell R, Gaestel M, Tsichlis P, Cominelli F, Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002;196:1563-74. [PMID: 12486099 DOI: 10.1084/jem.20020281] [Cited by in Crossref: 196] [Cited by in F6Publishing: 208] [Article Influence: 9.8] [Reference Citation Analysis]
237 Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003;17:105-17. [PMID: 12617886 DOI: 10.1053/bega.2002.0345] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 3.1] [Reference Citation Analysis]
238 Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell. 2003;14:1790-1800. [PMID: 12802055 DOI: 10.1091/mbc.e02-09-0583] [Cited by in Crossref: 242] [Cited by in F6Publishing: 265] [Article Influence: 12.1] [Reference Citation Analysis]
239 Papadakis KA, Abreu MT. Systemic consequences of intestinal inflammation. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/978-1-4020-3477-0_12] [Reference Citation Analysis]
240 Berczi I, Szentivanyi A. Cytokines and chemokines. The Immune-Neuroendocrine Circuitry History and Progress. Elsevier; 2003. pp. 191-220. [DOI: 10.1016/s1567-7443(03)80049-2] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
241 Hopman WPM, Jong DJ, Naber AHJ, J B M J Jansen. Tumour Necrosis Factor Alpha Antibody Affects Gastrin Release in Crohn Disease. Scand J Gastroenterol 2003;38:522-5. [PMID: 28443771 DOI: 10.1080/00365520310002896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
242 Papadakis KA, Abreu MT. Systemic consequences of intestinal inflammation. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/0-387-25808-6_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Gale JD, Mcclure KF, Pullen N. Chapter 15. Emerging opportunities for the treatment of inflammatory bowel disease. Annual Reports in Medicinal Chemistry 2003. [DOI: 10.1016/s0065-7743(03)38016-9] [Reference Citation Analysis]
244 Gockel H, Lügering A, Kucharzik T, Heidemann J, Domschke W, Lügering N. Thalidomid und Morbus Crohn. Chronisch entzündliche Darmerkrankungen 2003. [DOI: 10.1007/978-3-642-19025-4_14] [Reference Citation Analysis]
245 Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 2002;61:960-7. [PMID: 12379516 DOI: 10.1136/ard.61.11.960] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 2.9] [Reference Citation Analysis]
246 Savard CE, Blinman TA, Choi HS, Lee SK, Pandol SJ, Lee SP. Expression of cytokine and chemokine mRNA and secretion of tumor necrosis factor-alpha by gallbladder epithelial cells: response to bacterial lipopolysaccharides. BMC Gastroenterol. 2002;2:23. [PMID: 12377103 DOI: 10.1186/1471-230X-2-23] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
247 Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, Stuart RC, Wright N, Harrison R, Jankowski JA. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene. 2002;21:6071-6081. [PMID: 12203119 DOI: 10.1038/sj.onc.1205731] [Cited by in Crossref: 132] [Cited by in F6Publishing: 143] [Article Influence: 6.3] [Reference Citation Analysis]
248 Caprilli R, Viscido A, Guagnozzi D. Review article: biological agents in the treatment of Crohn's disease. Aliment Pharmacol Ther 2002;16:1579-90. [PMID: 12197837 DOI: 10.1046/j.1365-2036.2002.01319.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
249 Anderson MR, Jankowski JA. The treatment, management and prevention of oesophageal cancer. Expert Opin Biol Ther. 2001;1:1017-1028. [PMID: 11728233 DOI: 10.1517/14712598.1.6.1017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
250 Hollander D. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg? Am J Gastroenterol 2002;97:1867-8. [PMID: 12190145 DOI: 10.1111/j.1572-0241.2002.05895.x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
251 Chiche J, Pingat J, Cariou A, Mira J. Genetic Predisposition to Severe Sepsis. Clinical Pulmonary Medicine 2002;9:229-237. [DOI: 10.1097/00045413-200207000-00006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
252 Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, Sato N. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology 2002;123:291-300. [PMID: 12105857 DOI: 10.1053/gast.2002.34161] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 3.2] [Reference Citation Analysis]
253 Bush TG. Enteric glial cells. An upstream target for induction of necrotizing enterocolitis and Crohn’s disease? Bioessays. 2002;24:130-140. [PMID: 11835277 DOI: 10.1002/bies.10039] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 1.8] [Reference Citation Analysis]
254 Ridyard AE, Nuttall TJ, Else RW, Simpson JW, Miller HR. Evaluation of Th1, Th2 and immunosuppressive cytokine mRNA expression within the colonic mucosa of dogs with idiopathic lymphocytic–plasmacytic colitis. Veterinary Immunology and Immunopathology 2002;86:205-14. [DOI: 10.1016/s0165-2427(02)00039-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 1.7] [Reference Citation Analysis]
255 Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol. 2002;168:5342-5351. [PMID: 11994493 DOI: 10.4049/jimmunol.168.10.5342] [Cited by in Crossref: 291] [Cited by in F6Publishing: 308] [Article Influence: 13.9] [Reference Citation Analysis]
256 Kim S, Ferry G. Inflammatory bowel diseases in children. Curr Probl Pediatr Adolesc Health Care 2002;32:108-32. [PMID: 11981533 DOI: 10.1067/mps.2002.122638] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
257 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 229] [Cited by in F6Publishing: 238] [Article Influence: 10.9] [Reference Citation Analysis]
258 Cariou A, Chiche J, Charpentier J, Dhainaut J, Mira J. The era of genomics: Impact on sepsis clinical trial design: . Critical Care Medicine 2002;30:S341-8. [DOI: 10.1097/00003246-200205001-00026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 1.7] [Reference Citation Analysis]
259 Abreu MT, Arnold ET, Thomas LS, Gonsky R, Zhou Y, Hu B, Arditi M. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem. 2002;277:20431-20437. [PMID: 11923281 DOI: 10.1074/jbc.m110333200] [Cited by in Crossref: 280] [Cited by in F6Publishing: 294] [Article Influence: 13.3] [Reference Citation Analysis]
260 Mueller C. Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 2002;105:1-8. [PMID: 11849309 DOI: 10.1046/j.1365-2567.2002.01329.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 2.0] [Reference Citation Analysis]
261 Foxman EF, Zhang M, Hurst SD, Muchamuel T, Shen D, Wawrousek EF, Chan C, Gery I. Inflammatory Mediators in Uveitis: Differential Induction of Cytokines and Chemokines in Th1- Versus Th2-Mediated Ocular Inflammation. J Immunol 2002;168:2483-92. [DOI: 10.4049/jimmunol.168.5.2483] [Cited by in Crossref: 85] [Cited by in F6Publishing: 99] [Article Influence: 4.0] [Reference Citation Analysis]
262 Shi L, Kishore R, McMullen MR, Nagy LE. Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages: contribution to enhanced tumor necrosis factor alpha production. J Biol Chem 2002;277:14777-85. [PMID: 11856733 DOI: 10.1074/jbc.M108967200] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 2.5] [Reference Citation Analysis]
263 Konturek PC, Brzozowski T, Duda A, Kwiecien S, Löber S, Dembinski A, Hahn EG, Konturek SJ. Epidermal growth factor and prostaglandin E(2) accelerate mucosal recovery from stress-induced gastric lesions via inhibition of apoptosis. J Physiol Paris 2001;95:361-7. [PMID: 11595461 DOI: 10.1016/s0928-4257(01)00049-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
264 Sturm A, Fiocchi C. Life and death in the gut: more killing, less Crohn's. Gut 2002;50:148-9. [PMID: 11788550 DOI: 10.1136/gut.50.2.148] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
265 Triggiani M, Granata F, Oriente A, Gentile M, Petraroli A, Balestrieri B, Marone G. Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes. Eur J Immunol 2002;32:67-76. [DOI: 10.1002/1521-4141(200201)32:1<67::aid-immu67>3.0.co;2-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 2.3] [Reference Citation Analysis]
266 Kishore R, Hill JR, McMullen MR, Frenkel J, Nagy LE. ERK1/2 and Egr-1 contribute to increased TNF-alpha production in rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol 2002;282:G6-15. [PMID: 11751152 DOI: 10.1152/ajpgi.00328.2001] [Cited by in Crossref: 90] [Cited by in F6Publishing: 101] [Article Influence: 4.3] [Reference Citation Analysis]
267 Boone DL, Dassopoulos T, Lodolce JP, Chai S, Chien M, Ma A. Interleukin-2-deficient mice develop colitis in the absence of CD28 costimulation. Inflamm Bowel Dis 2002;8:35-42. [PMID: 11837936 DOI: 10.1097/00054725-200201000-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
268 Shetty A, Forbes A. Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn???s Disease: . American Journal of PharmacoGenomics 2002;2:215-21. [DOI: 10.2165/00129785-200202040-00001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
269 Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol. 2001;159:2001-2009. [PMID: 11733350 DOI: 10.1016/s0002-9440(10)63051-9] [Cited by in Crossref: 349] [Cited by in F6Publishing: 368] [Article Influence: 15.9] [Reference Citation Analysis]
270 Akobeng A, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd003574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
271 Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57. [PMID: 11677207 DOI: 10.1053/gast.2001.28702] [Cited by in Crossref: 407] [Cited by in F6Publishing: 440] [Article Influence: 18.5] [Reference Citation Analysis]
272 Wada K, Nakajima A, Blumberg RS. PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med. 2001;7:329-331. [PMID: 11516972 DOI: 10.1016/s1471-4914(01)02076-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 54] [Article Influence: 2.0] [Reference Citation Analysis]
273 Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFalpha. Eur J Cancer Prev 2001;10:163-6. [PMID: 11330458 DOI: 10.1097/00008469-200104000-00008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
274 Fiorucci S, Distrutti E, Ajuebor MN, Mencarelli A, Mannucci R, Palazzetti B, Del Soldato P, Morelli A, Wallace JL. NO-mesalamine protects colonic epithelial cells against apoptotic damage induced by proinflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2001;281:G654-65. [PMID: 11518677 DOI: 10.1152/ajpgi.2001.281.3.G654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
275 Folch E, Closa D. [New pathogenic concepts of pulmonary lesions in acute pancreatitis]. Gastroenterol Hepatol 2001;24:312-7. [PMID: 11459569 DOI: 10.1016/s0210-5705(01)70181-1] [Reference Citation Analysis]
276 van Heel DA, Mcgovern DP, Jewell DP. Crohn's disease: genetic susceptibility, bacteria, and innate immunity. The Lancet 2001;357:1902-4. [DOI: 10.1016/s0140-6736(00)05091-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
277 Weaver SA, Russo MP, Wright KL, Kolios G, Jobin C, Robertson DA, Ward SG. Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells. Gastroenterology 2001;120:1117-27. [PMID: 11266376 DOI: 10.1053/gast.2001.23257] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 2.1] [Reference Citation Analysis]
278 Kirsner JB. Etiology and Pathogenesis of IBD — Origins and Directions. Origins and Directions of Inflammatory Bowel Disease 2001. [DOI: 10.1007/978-94-010-0326-1_4] [Reference Citation Analysis]
279 Chiche JD, Siami S, Dhainaut JF, Mira JP. Cytokine Polymorphisms and Susceptibility to Severe Infectious Diseases. Sepsis (Boston) 2001;4:209-15. [PMID: 32288621 DOI: 10.1023/A:1013222407924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]